surveillance reporting, nationwide RSV prevention programs are not
optimal. A nationwide surveillance program was initiated to track and
report RSV activity at the local level in a timely manner. This
abstract includes an interim report of the data collected to date.
-- Regional Respiratory Syncytial Virus Surveillance Data for Georgia and
Implications for Prophylactic Administration of Palivizumab (Poster
#P32) - Mark Eggleston, PharmD, MBA, Saturday, October 27th, 2007 from
12:15 - 1:00 p.m.
BACKGROUND: The Georgia Division of Public Health initiated an RSV
surveillance program in mid-2000 to monitor RSV activity within four
regions of the state. This study aimed to identify the onset, duration,
and peak month of the RSV season in each of the four regions and
evaluate whether national guidelines for RSV prophylaxis with Synagis
are sufficient or whether recommendations should be based on local RSV
Additional information about the 2007 AAP National Conference & Exhibition can be found at http://www.aap.org/nce/.
MedImmune's Commitment to RSV Prevention
MedImmune is a world leader in the development of innovative
therapeutic biologic products to prevent RSV disease. In 1996, MedImmune
launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus
immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal
antibody administered via four-hour intravenous infusion. In 1998,
MedImmune introduced Synagis, which was a significant product improvement
as a monthly intramuscular injection for the prevention of severe RSV, as
well as being the first MAb to receive U.S. Food and Drug Administration
(FDA) approval for an infectious disease. With the ongoing development of
|SOURCE MedImmune, Inc.|
Copyright©2007 PR Newswire.
All rights reserved